5 most popular innovation stories in Houston this week

What's trending

From Houston getting a new biotech accelerator to events you can't miss this month, here's what news trended this week. Photo by PeopleImages

Editor's note: Houston began October with a flurry of innovation news stories, from a new accelerator being launched in town and three innovators to know to events not to miss and a name change for a Houston company. Here are this week's top stories.

3 Houston innovators to know this week

This week's Houston innovators are bringing new exciting things to town. Courtesy photos

New and exciting things are coming to town — from a data-focused conference two two startup development organizations announcing a Houston presence. Here are three Houston innovators making it happen in town. Click here to continue reading.

10+ can't-miss Houston business and innovation events for October

Check out these conferences, pitch competitions, networking, and more. Getty Images

October is another busy one for Houston innovation. Data-focused conferences, a rescheduled grand opening for The Cannon, and so much more. Click here to continue reading.

Exclusive: Houston sports tech company rebrands to attract a wider range of clients

FanReact is now Truss, and the company will be able to reach a greater audience. Photo courtesy of Truss

A Houston company that's specialized in digital sports fan engagement is reinventing itself to grow its client base.

FanReact, which earlier this year spun off its esports business into a new company called Mainline, is now known as Truss. The transition opens doors for the company to reach new clients that aren't in the sports industry — but that maybe want to take a page out of the fan experience's book. Click here to continue reading.

Houston millionaire starts biotech accelerator for companies focusing on regenerative medicine

The new biotech accelerator has already worked with two companies, which have relocated their operations to Houston. Getty Images

A new Houston-based startup accelerator is planning to advance companies focusing on regenerative medicine and stem cell treatment.

Houston Healthspan Innovation Group was created by founder and CEO Ed Bosarge, a local entrepreneur who's made millions of developing health care and finance technology. Click here to continue reading.

Health insurance tech startup taps Texas for its launch due to its large uninsured population

California-based Sidecar Health has rolled out its health insurance tech services in Texas. Images via sidecarhealth.com

The health insurance situation in Texas is anemic.

Last year, 17.7 percent of Texans lacked health insurance, according to newly released data from the U.S. Census Bureau. That's the highest rate of uninsured residents among all of the states.

The problem is even more acute in the Houston metro area. In 2018, nearly 1 in 5 residents of the region (18.6 percent) had no health insurance, the Census Bureau says. That's the highest rate of uninsured residents among the country's 25 most populous metro areas.

If you do the math, that translates into more than 5 million residents of Texas, including more than 1.3 million in the Houston area, who have no health-insurance safety net. A startup called Sidecar Health is setting out to reduce those numbers. Click here to continue reading.

This week's Houston innovators are bringing new exciting things to town. Courtesy photos

3 Houston innovators to know this week

who's who

James Y. Lancaster, Texas branch manager of VIC Technology Venture Development

A new venture development company has expanded into Houston with a Texas Medical Center office. Photo courtesy of James Lancaster

An Arkansas-based technology venture development firm had its eyes on Dallas for a Texas expansion, but James Y. Lancaster had a bigger plan. Lancaster, who was named as VIC Technology Venture Development's Texas branch manager, oversees the company's business in Dallas, Houston, and College Station, where he lives. Locally, he will work out of a TMC Innovation Institute office.

"I am excited to be working to TMC member institutions to provide a new avenue for commercializing their technologies, expanding on our fast start in Texas with an exciting opportunity in the Houston innovation ecosystem," Lancaster says in a release.

VIC specializes in taking university-founded research innovations to the marketplace by partnering with technology and business experts at every stage of the process. Read more.

Suzette Cotto, CEO of Innovate Social Media

Houston's DataCon can help prepare business leaders for the digital revolution in AI and machine learning. Photo courtesy of Suzette Cotto

Suzette Cotto, in a guest column for InnovationMap, warns of a not-so-distant future where artificial intelligence and machine learning are a daily business requirement. As companies ready themselves for this digital commonplace, its the C-suite that needs to do some homework in preparation.

DataCon Houston, which takes place on October 10, is one way for C-level execs to get some information. The annual conference brings important concepts around AI and Automation to business leaders, according to Cotto.

"The target audience is not IT professionals, although there will be some in attendance; it's meant primarily to help the C-suite and non-technical leaders know where to begin and where to find that new vocabulary and translative resources," Cotto writes. "AI will affect every person in every business, and we must be ready for the cultural shifts that will come with the technological shifts." Read more.

Ed Bosarge, founder and CEO of Houston Healthspan Innovation Group

Houston millionaire and serial entrepreneur Ed Bosarge has launched a new biotech accelerator. Courtesy of Houston Healthspan Innovation Group

A serial entrepreneur, Ed Bosarge has launched his latest venture. The Houston Healthspan Innovation Group is a biotech startup accelerator for companies in the regenerative medicine industry.

"From day one, Houston Healthspan will play a significant role in shaping Houston's vibrant life sciences scene with its seasoned leadership and state-of-the-art facilities," Bosarge says in a news release. "Houston Healthspan may be a tipping point for the region's life sciences community."

According to the release, the organization has already worked with two companies that have relocated their office to Houston. Read more.

Houston's DataCon can help prepare business leaders for the digital revolution in AI and machine learning. Getty Images

Houston companies need to get ready for an artificial intelligence and machine learning revolution

The future is now

Looming on the horizon is a data tsunami coming towards us at breakneck speed. Companies have worked hard to keep up, creating digital transformation, taking manual processes from desktops, clipboards, and the paper paradigm to the Cloud. We're now sitting on huge quantities of idle bits of information called dark data. It's over collected and unused data that has the potential power to create decision-making brilliance.

Business leaders are attempting to optimize siloed data – unrelated data collected in databases and spreadsheets or obsolete apps, to make critical decisions. We currently connect these siloes with other systems using a data processing step called ETL – Extract, Transform and Load. Take the data from one place, transform it so it can relate to another data resource and then load that data to another place for analysis. It's a big, time consuming, intermediary step we have figured out how to circumvent. "NoETL" technology is the next-generation magic wand of machine thinking and it's a game-changer.

As non-technical business leaders, we rely on our partners in IT to give us meaningful data that charts our course. They've been our faithful navigators. We've made the recommended investment in IT infrastructure and technology and counted on receiving analytics that will result in winning outcomes. It's now time to sit down at the table and have new conversations with IT leadership around AI.

A tectonic shift

We are now in a new place. AI has come upon us quickly and the promise of ROI is great. There are new technologies that give business leaders advantages never before realized. Data science is the new crystal ball to the future of business. Automation and machine learning are taking historical data to a look ahead using algorithms and mathematical modeling. It's a new predictive mindset. What business leader wouldn't want that crystal ball?

The real assets of your business exist not in better machines but in your current data stores which are like coal mines waiting for data science to turn those lumps of coal into data diamonds.

There are new vocabulary words associated with data analytics. Data science thought leaders are preparing the way for businesses to have learning opportunities and to know which resources to tap for direction in creating new competitive dynamics. Don't wait too long to be curious. The early adopters are already a step ahead and the competitive marketplace is changing in unexpected ways.

Leadership resources for the implementation of AI

Legacy businesses with data lakes are ripe for action. Who should lead the charge? It's up to the C-suite to have intentional conversations around data science. It's up to leadership to be ready to speak and understand new concepts and vocabulary combined with leaps of faith needed to join the new world order of information.

Learning resources

Proactively look for learning opportunities. There are no excuses for not taking the initiative. No matter where you are in your career – this isn't something to linger about.

One upcoming seminar around AI and automation collaboration and education is DataCon Houston. It's an annual conference that brings important concepts around AI and Automation to business leaders. The target audience is not IT professionals, although there will be some in attendance; it's meant primarily to help the C-suite and non-technical leaders know where to begin and where to find that new vocabulary and translative resources. AI will affect every person in every business, and we must be ready for the cultural shifts that will come with the technological shifts.

Authors and thought leaders — George Danner, Dave McComb, and Gerald Kane will be speaking at DataCon October 10, 2019. In addition, Javier Fadul, director of innovation for HTX Labs will be speaking about XR and data visualization and its use in training employees and creating safer workplaces. Stefanos Damianakis will be teaching machine learning 101 and Juan Sequeda, principal scientist of data.world will present his UltraWrap NoETL patented technology.

Solving the unsolvable

The future of decision-making will render in blinks of an eye. Problems we thought unsolvable will suddenly have answers. Business leaders must get behind the leap of faith required for our own companies and push learning and understanding forward across the organization at all levels. AI and machine learning are the vortex of change. Are you ready for AI?

------

Suzette Cotto is CEO of Innovate Social Media, a digital marketing agency specializing marketing for startups in the medical, technology, and energy industries. For more information on DataCon Houston 2019, please visit: https://incitelogix.com/datacon-houston-2019/

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston health tech innovator collaborates on promising medical device funded by DOD

team work

The United States Department of Defense has awarded a grant that will allow the Texas Heart Institute and Rice University to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation and are a long-term option in end-stage heart failure.

The grant is part of the DOD’s Congressionally Directed Medical Research Programs (CDMRP). It was awarded to Georgia Institute of Technology, one of four collaborators on the project that will be designed and evaluated by the co-investigator Yaxin Wang. Wang is part of O.H. “Bud” Frazier’s team at Texas Heart Institute, where she is director of Innovative Device & Engineering Applications Lab. The other institution working on the new LVAD is North Carolina State University.

The project is funded by a four-year, $7.8 million grant. THI will use about $2.94 million of that to fund its part of the research. As Wang explained to us last year, an LVAD is a minimally invasive device that mechanically pumps a person’s own heart. Frazier claims to have performed more than 900 LVAD implantations, but the devices are far from perfect.

The team working on this new research seeks to minimize near-eventualities like blood clot formation, blood damage, and driveline complications such as infection and limitations in mobility. The four institutions will try to innovate with a device featuring new engineering designs, antithrombotic slippery hydrophilic coatings (SLIC), wireless power transfer systems, and magnetically levitated driving systems.

Wang and her team believe that the non-contact-bearing technology will help to decrease the risk of blood clotting and damage when implanting an LVAD. The IDEA Lab will test the efficacy and safety of the SLIC LVAD developed by the multi-institutional team with a lab-bench-based blood flow loop, but also in preclinical models.

“The Texas Heart Institute continues to be a leading center for innovation in mechanical circulatory support systems,” said Joseph G. Rogers, MD, the president and CEO of THI, in a press release.

“This award will further the development and testing of the SLIC LVAD, a device intended to provide an option for a vulnerable patient population and another tool in the armamentarium of the heart failure teams worldwide.”

If it works as hypothesized, the SLIC LVAD will improve upon current LVAD technology, which will boost quality of life for countless heart patients. But the innovation won’t stop there. Technologies that IDEA Lab is testing include wireless power transfer for medical devices and coatings to reduce blood clotting could find applications in many other technologies that could help patients live longer, healthier lives.

Houston investor on SaaS investing and cracking product-market fit

Houston innovators podcast episode 230

Aziz Gilani's career in tech dates back to when he'd ride his bike from Clear Lake High School to a local tech organization that was digitizing manuals from mission control. After years working on every side of the equation of software technology, he's in the driver's seat at a local venture capital firm deploying funding into innovative software businesses.

As managing director at Mercury, the firm he's been at since 2008, Gilani looks for promising startups within the software-as-a-service space — everything from cloud computing and data science and beyond.

"Once a year at Mercury, we sit down with our partners and talk about the next investment cycle and the focuses we have for what makes companies stand out," Gilani says on the Houston Innovators Podcast. "The current software investment cycle is very focused on companies that have truly achieved product-market fit and are showing large customer adoption."

An example of this type of company is Houston-based RepeatMD, which raised a $50 million series A round last November. Mercury's Fund V, which closed at an oversubscribed $160 million, contributed to RepeatMD's round.

"While looking at that investment, it really made me re-calibrate a lot of my thoughts in terms what product-market fit meant," Gilani says. "At RepeatMD, we had customers that were so eager for the service that they were literally buying into products while we were still making them."

Gilani says he's focused on finding more of these high-growth companies to add to Mercury's portfolio amidst what, admittedly, has been a tough time for venture capital. But 2024 has been looking better for those fundraising.

"We've some potential for improvement," Gilani says. "But overall, the environment is constrained, interest rates haven't budged, and we've seen some potential for IPO activity."

Gilani shares more insight into his investment thesis, what areas of tech he's been focused on recently, and how Houston has developed as an ecosystem on the podcast.

Houston startup scores $12M grant to support clinical evaluation of cancer-fighting drug

fresh funding

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.”

The antibody, called 4A10, was invented by Scott Durum PhD and his team at the National Cancer Institute (NCI). Licensed exclusively by Allterum, a company launched by Fannin, 4A10 is a novel immunotherapy that utilizes a patient’s own immune system to locate and kill cancer cells.

Varadhachary explained that while about 80 percent of patients afflicted with ALL have the B-cell version, the other 20 percent suffer from T-cell ALL.

“Because the TLL population is so small, there are really no approved, effective drugs for it. The last drug that was approved was 18 or 19 years ago,” the CEO-scientist said. 4A10 addresses this unmet need, but also goes beyond it.

Because 4A10 targets CD127, also known as the interleukin-7 receptor, it could be useful in the treatment of myriad cancers. In fact, the receptor is expressed not just in hematological cancers like ALL, but also solid tumors like breast, lung, and colorectal cancers. There’s also “robust data,” according to Varadhachary for the antibody’s success against B-cell ALL, as well as many other cancers.

“Now what we're doing in parallel with doing the development for ALL is that we're continuing to do additional preclinical work in these other indications, and then at some point, we will raise a series A financing that will allow us to expand markets into things which are much more commercially attractive,” Varadhachary explains.

Why did they go for the less commercially viable application first? As Varadhachary put it, “The Fannin model is to allow us to go after areas which are major unmet medical needs, even if they are not necessarily as attractive on a commercial basis.”

But betting on a less common malady could have a bigger payoff than the Allterum team originally expected.

Before the new CPRIT grant, Allterum’s funding included a previous seed grant from CPRIT of $3 million. Other funds included an SBIR grant from NCI, as well as another NCI program called NExT, which deals specifically with experimental therapies.

“To get an antibody from research into clinical testing takes about $10 million,” Varadhachary says. “It's an expensive proposition.”

With this, and other nontraditional financing, the company was able to take what Varadhachary called “a huge unmet medical need but a really tiny commercial market” and potentially help combat a raft of other childhood cancers.

“That's our vision. It's not economically hugely attractive, but we think it's important,” says Varadhachary.

Atul Varadhachary is the managing director of Fannin Innovation. Photo via LinkedIn

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME